Anticipates initiating the Company's Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for ...

At this time, I would like to welcome everyone to the Katapult Holdings first quarter 2025 earnings conference call. All lines have been placed on mute to prevent any background noise. After the ...